Inhibition of retinal neovascularization by VEGF siRNA delivered via bioreducible lipid-like nanoparticles
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibition of retinal neovascularization by VEGF siRNA delivered via bioreducible lipid-like nanoparticles
Authors
Keywords
-
Journal
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-03
DOI
10.1007/s00417-020-04797-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Retinopathy of Prematurity: A Review of Risk Factors and their Clinical Significance
- (2018) Sang Jin Kim et al. SURVEY OF OPHTHALMOLOGY
- Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity
- (2018) Andreas Stahl et al. JAMA Pediatrics
- Retinal Vasculature in Development and Diseases
- (2018) Ye Sun et al. Annual Review of Vision Science
- Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing
- (2017) Samantha M. Sarett et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A new layer of rRNA regulation by small interference RNAs and the nuclear RNAi pathway
- (2017) Xufei Zhou et al. RNA Biology
- Progress and perspective of inorganic nanoparticle-based siRNA delivery systems
- (2016) Ying Jiang et al. Expert Opinion on Drug Delivery
- Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity
- (2016) Kay D. Beharry et al. SEMINARS IN PERINATOLOGY
- Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown
- (2015) Anders Wittrup et al. NATURE BIOTECHNOLOGY
- Pathophysiology and Mechanisms of Severe Retinopathy of Prematurity
- (2015) M. Elizabeth Hartnett OPHTHALMOLOGY
- Enhanced Intracellular siRNA Delivery using Bioreducible Lipid-Like Nanoparticles
- (2014) Ming Wang et al. Advanced Healthcare Materials
- The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge
- (2013) Giacomo Cavallaro et al. ACTA OPHTHALMOLOGICA
- Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010
- (2013) Hannah Blencowe et al. PEDIATRIC RESEARCH
- Vascular endothelial growth factor and insulin-like growth factor-1 in preterm infants with retinopathy of prematurity
- (2013) A Peirovifar et al. SINGAPORE MEDICAL JOURNAL
- VEGF-Mediated STAT3 Activation Inhibits Retinal Vascularization by Down-Regulating Local Erythropoietin Expression
- (2012) Haibo Wang et al. AMERICAN JOURNAL OF PATHOLOGY
- Combinatorial Library of Lipidoids for In Vitro DNA Delivery
- (2011) Shuo Sun et al. BIOCONJUGATE CHEMISTRY
- Avastin as monotherapy for retinopathy of prematurity
- (2010) Helen A. Mintz-Hittner JOURNAL OF AAPOS
- Endocytosis of nanomedicines
- (2010) Gaurav Sahay et al. JOURNAL OF CONTROLLED RELEASE
- The effects of oxygen stresses on the development of features of severe retinopathy of prematurity: knowledge from the 50/10 OIR model
- (2009) M. Elizabeth Hartnett DOCUMENTA OPHTHALMOLOGICA
- The development of the rat model of retinopathy of prematurity
- (2009) Joshua M. Barnett et al. DOCUMENTA OPHTHALMOLOGICA
- COMBINATION THERAPY USING THE SMALL INTERFERING RNA BEVASIRANIB
- (2009) LAWRENCE SINGERMAN RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Intravitreous Bevacizumab as Anti–Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity: A Morphologic Study
- (2008) Lingkun Kong ARCHIVES OF OPHTHALMOLOGY
- Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome
- (2008) J M Ruiz-Moreno et al. BRITISH JOURNAL OF OPHTHALMOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started